Canadian Investment Review

CPPIB investing in Canadian precision oncology company

Written by Benefits Canada Staff on Tuesday, January 14th, 2020 at 9:34 am

 Micro tubes with biological samples in laboratory for DNA analys © Alexander Traksel /123RF Stock PhotosThe Canada Pension Plan Investment Board is investing US$20 million in Fusion Pharmaceuticals Inc., a Hamilton, Ont.-based precision oncology company.

The funds will go towards expanding the use of the company’s radiopharmaceutical platform, which attaches medical isotopes to targeting molecules to kill solid tumour cells.

“CPPIB’s investment reflects strong support for Fusion’s platform technology and people and demonstrates momentum in the radiopharmaceutical industry,” said John Valliant, Fusion’s chief executive officer, in a press release. “The additional capital provides opportunities for Fusion to accelerate our growth plans and our pipeline of novel and combination therapy assets that can deliver effective and personalized radiation therapies to cancer patients.”

This article originally appeared on CIR’s companion site, Benefitscanada.com. Read the full story here.

 

Copyright 2020. Canadian Investment Review. All Rights Reserved.